4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Sell (E+)” Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (e+)” rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

A number of other analysts also recently commented on FDMT. Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Leerink Partners decreased their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. Chardan Capital decreased their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.63.

4D Molecular Therapeutics Stock Up 4.5 %

Shares of 4D Molecular Therapeutics stock opened at $3.92 on Friday. 4D Molecular Therapeutics has a 52-week low of $3.58 and a 52-week high of $36.25. The company’s 50-day simple moving average is $4.69 and its 200-day simple moving average is $7.39. The firm has a market cap of $181.50 million, a price-to-earnings ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). Equities research analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Decheng Capital LLC lifted its holdings in shares of 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock valued at $2,228,000 after purchasing an additional 2,165 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock valued at $247,000 after buying an additional 2,925 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares during the last quarter. Rhumbline Advisers raised its position in shares of 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after buying an additional 3,675 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 30.1% in the fourth quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after buying an additional 3,783 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.